Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373661 | 1.00 | TACR1 (0.44) | TACR1P2RX3USP2CYP1A2CYP2C19 | |
| SCHEMBL13891620 | 0.98 | TACR1 (0.43) | TACR1P2RX3USP2CYP1A2CYP2C19 | |
| SCHEMBL15680049 | 0.96 | TACR1 (0.41) | TACR1P2RX3USP2CYP1A2CYP2C19 | |
| SCHEMBL13891767 | 0.90 | P2RX3 (0.40) | P2RX3PIK3R1MTOR | |
| SCHEMBL13891719 | 0.89 | TACR1 (0.48) | TACR1 | |
| SCHEMBL13891721 | 0.89 | HTT (0.37) | P2RX3PIK3R1MTOR | |
| SCHEMBL5527526 | 0.87 | TACR1 (0.43) | TACR1USP2CYP1A2CYP2C19MET | |
| SCHEMBL5230814 | 0.87 | TACR1 (0.44) | TACR1P2RX3USP2CYP1A2CYP2C19 | |
| SCHEMBL13891688 | 0.86 | TACR1 (0.41) | TACR1TSHR | |
| SCHEMBL5228486 | 0.86 | TACR1 (0.44) | TACR1P2RX3USP2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-01-21 | — | — | US | disclosed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| US-20140128395-A1 | Novel Method | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | US | disclosed |
| WO-2005019225-A1 | PROCESS FOR PRODUCING COMPOUND HAVING NK1 RECEPTOR ANTAGONISM AND PRODUCTION INTERMEDIATE THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128395-A1 | Novel Method | BAK1, VIPR1, BDKRB1 | TACR1 38/4885P2RX3 600/4885USP2 4511/4885 |
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OPRK1, OPRL1, KLKB1 | TACR1 18/4885P2RX3 29/4885USP2 4064/4885 |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | TACR1 119/4885P2RX3 784/4885USP2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.